Jazz Pharmaceuticals plc

JAZZ · NASDAQ

Jazz Pharmaceuticals reported 2025 revenue of $4.27 billion and Q1 2026 revenue of $1.07 billion. The thesis turns on whether specialty medicines, pipeline investment and portfolio execution can convert strong cash generation into durable earnings after a loss-making annual operating baseline.

Follow Add to Watchlist Ask Question

NASDAQ JAZZ Coverage Bootstrap Jazz Pharmaceuticals plc

Latest ReportMay 20, 2026Jazz Pharmaceuticals: specialty pharma cash flow needs pipeline and portfolio proofView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 company reports

Add tags

Latest Thesis

Jazz Pharmaceuticals: specialty pharma cash flow needs pipeline and portfolio proof

May 20, 2026Research reportSlides available

Read report Open slides Discussion (0)

Jazz Pharmaceuticals plcPharmaceuticals: specialty pharma cash flow needs pipeline and pMay 20, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

ReportTypeUpdatedReadActions

Jazz Pharmaceuticals: specialty pharma cash flow needs pipeline and portfolio proofJazz Pharmaceuticals reported 2025 revenue of $4.27 billion and Q1 2026 revenue of $1.07 billion. The thesis turns on whether specialty medicines, pipeline investment and portfolio execution can convert strong cash generation into durable earnings after a loss-making annual operating baseline.NASDAQMay 20, 2026Research reportRead Slides